Biotech | August 08, 2021
TAKE divests stake in Navitas Life Sciences to HIG
The transaction is expected to close in the Q4FY22
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
CDSCO to fast-track trials and approval for COVID19 vaccine
Deal for 100 million doses with additional 100 million through 2023
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Subscribe To Our Newsletter & Stay Updated
